- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
+0.54| Last Update: 05/24/13 - 4:03 PM EDT |
| Volume: 216,858 |
| YTD Performance: -0.47% |
| Open: $67.53 |
| Previous Close: $67.73 |
| 52 Week Range: $54.06 - $82.00 |
| Oustanding Shares: 18,868,108 |
| Market Cap: 1,277,936,955 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.16 | $1.18 | $4.94 | $5.28 |
| Number of Analysts | 1 | 1 | 1 | 1 |
| High Estimate | $1.16 | $1.18 | $4.94 | $5.28 |
| Low Estimate | $1.16 | $1.18 | $4.94 | $5.28 |
| Prior Year | $1.18 | $1.20 | $5.04 | $4.94 |
| Growth Rate (Year over Year) | -1.69% | -1.67% | -1.98% | 6.88% |
Companies that provide end-of-life services have demographics on their side.
Chemed Corporation target raised at OppenheimerShares of CHE now seen reaching $91, Oppenheimer said. Fourth quarter beat. Outperform rating.
Chemed Corporation target raised at OppenheimerShares of CHE now seen reaching $80, Oppenheimer said. Bullish following management meetings. Outperform rating.
These stocks stand to benefit if Americans can accept the fact that rising health care costs aren't magically going away.
Recently accused of Medicare fraud, Chemed is facing costly legal problems.
Financial pain caused by a flat yield curve will cascade from the insurance industry into health care.
If only the entire economy felt as well.